Challenges associated with the treatment of Buruli ulcer

Journal of Leukocyte Biology
Sammy Yaw AboagyeDorothy Yeboah-Manu

Abstract

Buruli ulcer (BU), caused by Mycobacterium ulcerans (MU), is the third most important mycobacterial diseases after tuberculosis and leprosy in immunocompetent individuals. Although the mode of transmission remains an enigma, disease incidence has been strongly linked to disturbed environment and wetlands. The blunt of the diseases is recorded in West African countries along the Gulf of Guinea, and children 15 years and below account for about 48% of all cases globally. Prior to 2004, wide surgical excisions and debridement of infected necrotic tissues followed by skin grafting was the accepted definitive treatment of BU. However, introduction of antibiotic therapy, daily oral rifampicin (10 mg/kg) plus intramuscular injection of streptomycin (15 mg/kg), for 8 weeks by the WHO in 2004 has reduced surgery as an adjunct for correction of deformities and improved wound healing. An all-oral regimen is currently on clinical trial to replace the injectable. It is thought that a protective cloud of the cytotoxic toxin mycolactone kills infiltrating leucocytes leading to local immunosuppression and down-regulation of the systemic immune system. Our studies of lesions from BU patients treated with SR have demonstrated treatment-associate...Continue Reading

References

Aug 6, 1992·The New England Journal of Medicine·R Y Dodd
Feb 1, 1974·Annals of Surgery·C HeughanT K Hunt
Jan 1, 1993·Annual Review of Microbiology·L Katz, S Donadio
Sep 29, 1999·Lancet·T S van der WerfK Asiedu
Feb 17, 2001·Infection and Immunity·T M GoodingR M Robins-Browne
Mar 14, 2001·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·F Perri
Apr 9, 2001·Clinical Microbiology Reviews·P G BowlerD G Armstrong
Nov 8, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C A PettipherM Hopley
Feb 28, 2002·Annual Review of Immunology·Charles A Janeway, Ruslan Medzhitov
Jan 25, 2003·Antimicrobial Agents and Chemotherapy·Yanmin HuDenis A Mitchison
Mar 15, 2003·Clinics in Plastic Surgery·John L BurnsLinda G Phillips
Apr 10, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Travis M GoodingPaul D R Johnson
Jun 5, 2003·Emerging Infectious Diseases·Jeannette GuarnerDavid A Ashford
Mar 27, 1954·The Medical Journal of Australia·B R FORBESW B KIRKLAND
Feb 3, 2004·American Journal of Infection Control·Judith Morrison, UNKNOWN Health Canada, Nosocomial and Occupational Infections Section
Mar 17, 2004·Current Opinion in Infectious Diseases·Ruth Edwards, Keith G Harding
Aug 20, 2004·The New England Journal of Medicine·Susan L StramerUNKNOWN National Heart, Lung, and Blood Institute Nucleic Acid Test Study Group
Oct 22, 2004·Emerging Infectious Diseases·Martine DebackerFrançoise Portaels
Jan 12, 2005·Clinical and Diagnostic Laboratory Immunology·B Daan WestenbrinkTjip S van der Werf
Apr 13, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Charlotte R HawkeyRobert J Wilkinson
Apr 21, 2005·PLoS Medicine·Paul D R JohnsonKingsley Asiedu
Dec 24, 2005·Current Opinion in Infectious Diseases·Marc Lipman, Ronan Breen
Jan 6, 2006·Genes and Immunity·Y StienstraG van der Steege
Feb 16, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A C C CarvalhoA Matteelli
May 9, 2006·European Journal of Emergency Medicine : Official Journal of the European Society for Emergency Medicine·Yann-Erick ClaessensJean-Daniel Chiche
Dec 6, 2006·Infection and Immunity·Egídio TorradoJorge Pedrosa
May 23, 2007·The Journal of Experimental Medicine·Emmanuelle CoutanceauCaroline Demangel
Aug 21, 2007·British Journal of Pharmacology·A R M Coates, Y Hu
Sep 7, 2007·The New England Journal of Medicine·Peter J HotezLorenzo Savioli
Jan 24, 2008·Wound Repair and Regeneration : Official Publication of the Wound Healing Society [and] the European Tissue Repair Society·Stephen C DavisPatricia M Mertz
Mar 28, 2008·PLoS Neglected Tropical Diseases·Françoise PortaelsJorge Pedrosa

❮ Previous
Next ❯

Citations

Feb 1, 2019·Journal of Leukocyte Biology·Elopy Sibanda, Mohamed-Ridha Barbouche
May 27, 2020·PLoS Neglected Tropical Diseases·Shelui CollinsonRichard O Phillips
Aug 29, 2020·The International Journal of Lower Extremity Wounds·Awube MenlahMaame Kodua Boahemaa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Buruli Ulcer

Buruli ulcer is a progressive disease of subcutaneous tissues caused by mycobacterium ulcerans. Here is the latest research.